Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients

Rokx, Casper; van der Ende, Marchina; Verbon, Annelies; Rijnders, Bart

doi:10.1093/cid/cit517

C. Rokx (Casper), M.E. van der Ende (Marchina), A. Verbon (Annelies) and B.J.A. Rijnders (Bart)

2013-11-15

Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients

Clinical Infectious Diseases , Volume 57 - Issue 10 p. 1497- 1499

In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

Additional Metadata
Keywords	Highly active antire-troviral therapy, HIV/AIDS, Kaposi sarcoma, Peginterferon alfa-2a, Treatment effectiveness
Persistent URL	doi.org/10.1093/cid/cit517, hdl.handle.net/1765/62769
Journal	Clinical Infectious Diseases
Organisation	Department of Internal Medicine
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Rokx, C., van der Ende, M., Verbon, A., & Rijnders, B. (2013). Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients. Clinical Infectious Diseases, 57(10), 1497–1499. doi:10.1093/cid/cit517

Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients

Publication

Publication

About

Peginterferon Alfa-2a for AIDS-associated kaposi sarcoma: Experience with 10 patients

Publication

Publication

Workflow

Workflow

Add Content